BACKGROUND: Macroadenomas causing acromegaly are cured surgically in only around 50% of patients. Primary medical treatment with somatostatin analogues has been suggested to be a means of treating patients with a potentially poor surgical outcome. Previous retrospective studies have also suggested that surgical debulking of pituitary tumours causing acromegaly improves control by somatostatin analogues. No prospective study using lanreotide has been carried out thus far to assess whether this...Expand abstract
- Publication status:
- Publisher copy:
- Copyright date:
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
If you are the owner of this record, you can report an update to it here: Report update to this record